Trials / Unknown
UnknownNCT04108325
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A Single-Arm, Open-Label, Multi-Center, Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YY-20394 | Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable. |
Timeline
- Start date
- 2020-03-30
- Primary completion
- 2021-06-01
- Completion
- 2021-12-01
- First posted
- 2019-09-30
- Last updated
- 2021-01-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04108325. Inclusion in this directory is not an endorsement.